Literature DB >> 430201

Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancers.

J Nĕmec, S Röhling, V Zamrazil, D Pohunková.   

Abstract

In 206 patients with differentiated thyroid cancer, the distribution of iodine-131 were compared after diagnostic (200-500 microCi) and thyroblative (approximately 100 mCi) doses. In the diagnostic scans, only normal thyroid tissue could be seen, whereas in one-fourth of the patients the therapeutic scans showed tumor tissue as well, usually in lymphnode metastases. In 16% of patients, the therapeutic scan was the only way to demonstrate the presence of tumor tissue, since no further uptake was achievable. In patients in whom all tumor was believed to have been removed by surgery alone, a "preventive" I-131 ablation was used, and in 16 of these 97 patients tumor was revealed in the therapeutic scan. In ten more, tumor was found in subsequent followup scans, its functioning having been induced by destruction of postsurgical remnants of normal thyroid. Some possible explanations for the differences in scans are proposed, and the importance of therapeutic scans for correct staging of thyroid cancer is stressed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 430201

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  10 in total

Review 1.  Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Gary L Francis; Steven G Waguespack; Andrew J Bauer; Peter Angelos; Salvatore Benvenga; Janete M Cerutti; Catherine A Dinauer; Jill Hamilton; Ian D Hay; Markus Luster; Marguerite T Parisi; Marianna Rachmiel; Geoffrey B Thompson; Shunichi Yamashita
Journal:  Thyroid       Date:  2015-07       Impact factor: 6.568

2.  Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment.

Authors:  Leonardo Pace; Michele Klain; Carmine Albanese; Barbara Salvatore; Giovanni Storto; Andrea Soricelli; Marco Salvatore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-05       Impact factor: 9.236

3.  Reply.

Authors:  O Sabri
Journal:  Eur J Nucl Med       Date:  2001-03

4.  Post-operative diagnosis and therapy of thyroid carcinoma by nuclear medicine.

Authors:  H Hundeshagen
Journal:  Eur J Nucl Med       Date:  1983

5.  Metastatic involvement of the spleen in differentiated carcinoma of thyroid.

Authors:  Purushottam Kand; Ramesh Asopa
Journal:  Indian J Nucl Med       Date:  2010-10

Review 6.  The role of nuclear medicine in oncology.

Authors:  H J Biersack; B Briele; A L Hotze; P Oehr; L Qian; M A Mekkawy; W J Shih
Journal:  Ann Nucl Med       Date:  1992-08       Impact factor: 2.668

7.  Positive thyroid cancer scintigraphy using technetium-99m methoxyisobutylisonitrile.

Authors:  J Nĕmec; O Nývltová; T Blazek; P Vlcek; P Racek; Z Novák; M Preiningerová; M Hubácková; M Krízo; J Zimák; R Bílek
Journal:  Eur J Nucl Med       Date:  1996-01

8.  Improved detection of lung or bone metastases with an I-131 whole body scan on the 7th day after high-dose I-131 therapy in patients with thyroid cancer.

Authors:  Ari Chong; Ho-Chun Song; Jung-Joon Min; Shin Young Jeong; Jung-Min Ha; Jahae Kim; Su-Ung Yoo; Jong-Ryool Oh; Hee-Seung Bom
Journal:  Nucl Med Mol Imaging       Date:  2010-10-13

9.  Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans.

Authors:  Eun-Kyung Park; June-Key Chung; Il Han Lim; Do Joon Park; Dong Soo Lee; Myung Chul Lee; Bo Youn Cho
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-09-09       Impact factor: 9.236

10.  Do negative 124I pretherapy positron emission tomography scans in patients with elevated serum thyroglobulin levels predict negative 131I posttherapy scans?

Authors:  Gauri R Khorjekar; Douglas Van Nostrand; Carlos Garcia; Jeffrey O'Neil; Shari Moreau; Francis B Atkins; Mihriye Mete; Michael H Orquiza; Kenneth Burman; Leonard Wartofsky
Journal:  Thyroid       Date:  2014-06-20       Impact factor: 6.568

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.